These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18511176)

  • 1. Editorial comment on: surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
    Badalyan R
    Eur Urol; 2008 Nov; 54(5):1177-8. PubMed ID: 18511176
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
    Grabe M
    Eur Urol; 2008 Nov; 54(5):1176-7. PubMed ID: 18511182
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
    Novara G
    Eur Urol; 2008 Nov; 54(5):1175-6. PubMed ID: 18511181
    [No Abstract]   [Full Text] [Related]  

  • 4. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
    Naber KG; Schito G; Botto H; Palou J; Mazzei T
    Eur Urol; 2008 Nov; 54(5):1164-75. PubMed ID: 18511178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy.
    Neuzillet Y; Naber KG; Schito G; Gualco L; Botto H
    Med Mal Infect; 2012 Feb; 42(2):66-75. PubMed ID: 22264668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Russian results of the international epidemiological study of clinical aspects and resistance to antimicrobial medicines of cystitis uropathogens in females (ARESC): significance of empiric therapy].
    Perepanova TS; Siniakova LA; Zaĭtsev AV; Kozlov RS; Shevelev AN; Gualco L; Achito G; Naber KG
    Urologiia; 2011; (2):30-6. PubMed ID: 21815455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
    Schito GC; Naber KG; Botto H; Palou J; Mazzei T; Gualco L; Marchese A
    Int J Antimicrob Agents; 2009 Nov; 34(5):407-13. PubMed ID: 19505803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance and future of antimicrobial surveillance studies.
    Masterton R
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S21-31. PubMed ID: 18713046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent bacterial cystitis].
    Iwata S
    Iryo; 1969 Jun; 23(6):739-44. PubMed ID: 5821502
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimicrobial resistance in bacteria from pets and horses.
    Sternberg S
    Acta Vet Scand Suppl; 1999; 92():37-50. PubMed ID: 10783716
    [No Abstract]   [Full Text] [Related]  

  • 11. Turning the tide of antimicrobial resistance: Europe shows the way.
    Monnet D; Kristinsson K
    Euro Surveill; 2008 Nov; 13(46):. PubMed ID: 19021956
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimicrobial resistance: the need for a common strategy.
    Vet Rec; 1998 Sep; 143(12):318-9. PubMed ID: 9795399
    [No Abstract]   [Full Text] [Related]  

  • 13. [Norfloxacine efficacy in acute cystitis in the region with 10% resistance of E. coli to fluoroquinolones: a comparative randomized study].
    Rafal'skiĭ VV; Malev IV; Derevitskiĭ AV; Kozlov SN; Galkin VV
    Urologiia; 2009; (3):18-21. PubMed ID: 19670810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frequency of resistance to antimicrobial agents in bacteria, isolated from hospitalized patients and from outpatients (Zurich 1976) (author's transl)].
    Kayser FH; Wüst J; Munzinger J
    Schweiz Rundsch Med Prax; 1977 May; 66(22):669-75. PubMed ID: 876989
    [No Abstract]   [Full Text] [Related]  

  • 15. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to antimicrobial agents: can we make a difference?
    Chambers ST
    Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):207-21. PubMed ID: 11059360
    [No Abstract]   [Full Text] [Related]  

  • 17. An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():103-9. PubMed ID: 3980320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priorities for antibiotic resistance surveillance in Europe.
    Fluit AC; van der Bruggen JT; Aarestrup FM; Verhoef J; Jansen WT
    Clin Microbiol Infect; 2006 May; 12(5):410-7. PubMed ID: 16643516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monural--choice of treatment in acute cystitis].
    Akush Ginekol (Sofiia); 2009; 48(2):33. PubMed ID: 20198777
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development and prospects of antimicrobial therapy].
    Falisevac J
    Lijec Vjesn; 1970; 92(8):869-85. PubMed ID: 5207440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.